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Brian S. Finkelman, BS,* Brian F. Gage, MD, MSC,‡ Julie A. Johnson, PHARMD,§
Colleen M. Brensinger, MS,* Stephen E. Kimmel, MD, MSCE*†
Philadelphia, Pennsylvania; St. Louis, Missouri; and Gainesville, Florida
Objectives The aim of this study was to compare the accuracy of genetic tables and formal pharmacogenetic algorithms for
warfarin dosing.
Background Pharmacogenetic algorithms based on regression equations can predict warfarin dose, but they require detailed
mathematical calculations. A simpler alternative, recently added to the warfarin label by the U.S. Food and Drug
Administration, is to use genotype-stratified tables to estimate warfarin dose. This table may potentially increase
the use of pharmacogenetic warfarin dosing in clinical practice; however, its accuracy has not been quantified.
Methods A retrospective cohort study of 1,378 patients from 3 anticoagulation centers was conducted. Inclusion criteria
were stable therapeutic warfarin dose and complete genetic and clinical data. Five dose prediction methods
were compared: 2 methods using only clinical information (empiric 5 mg/day dosing and a formal clinical algo-
rithm), 2 genetic tables (the new warfarin label table and a table based on mean dose stratified by genotype),
and 1 formal pharmacogenetic algorithm, using both clinical and genetic information. For each method, the pro-
portion of patients whose predicted doses were within 20% of their actual therapeutic doses was determined.
Dosing methods were compared using McNemar’s chi-square test.
Results Warfarin dose prediction was significantly more accurate (all p  0.001) with the pharmacogenetic algorithm
(52%) than with all other methods: empiric dosing (37%; odds ratio [OR]: 2.2), clinical algorithm (39%; OR: 2.2),
warfarin label (43%; OR: 1.8), and genotype mean dose table (44%; OR: 1.9).
Conclusions Although genetic tables predicted warfarin dose better than empiric dosing, formal pharmacogenetic algorithms
were the most accurate. (J Am Coll Cardiol 2011;57:612–8) © 2011 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.08.643t
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rn August 2007, the U.S. Food and Drug Administration
pdated the warfarin (Coumadin, Bristol-Myers Squibb,
rinceton, New Jersey) product label to add pharmacoge-
etic information (1). In January 2010, the agency added
pecific instructions on how to use genotype to predict
ndividualized doses: the new label provides a concise table
f dosing recommendations, stratified by genotype (2). In
ontrast, most research on pharmacogenetic warfarin dosing
as focused on developing and validating complex predictive
lgorithms (3,4), which integrate clinical and genetic factors
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ollection, management, analysis, and interpretation of the data; and preparation, ao predict dose on the basis of regression equations. These
lgorithms accurately predict warfarin dose (4–8), although
hey may not be as accurate in African Americans (9).
Formal predictive algorithms require the use of a com-
uter or web-based application (10) to conduct mathemat-
cal calculations and are difficult to summarize in written
orm. Providing an estimated dose in a table, such as the one
n the new warfarin label, renders a genotype-specific dose
eadily accessible and easier to implement in clinical prac-
ice. However, no published study has quantified the accu-
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February 1, 2011:612–8 Genetic Warfarin Dosing: Tables Versus Algorithmsacy of the new table. As a result, clinicians prescribing
arfarin might increase their use of pharmacogenetic dosing
ithout a clear understanding of its accuracy.
In this study, we compared the accuracy of warfarin dose
rediction in a formal pharmacogenetic algorithm with 2
enetic tables, the aforementioned warfarin label table
reproduced in Table 1) and a similar table constructed from
he mean dose by genotype in a separate cohort (Table 2).
e also compared these dosing methods with 2 nongenetic
ethods: a clinical predictive algorithm and standard em-
iric dosing of 35 mg/week (11).
ethods
atient population. The cohort comprised 1,378 patients
aking warfarin at the University of Pennsylvania, the
niversity of Florida, and Washington University. Most of
hese patients were originally recruited as part of prior
rospective cohort studies (3,12–14), and many were also
ater included in the International Warfarin Pharmacoge-
etics Consortium cohort (accessed via PharmGKB acces-
ion number PA162355460) (4,15). Participants were re-
uired to have achieved a stable therapeutic dose of
arfarin, defined as the dose that led to therapeutic inter-
ational normalized ratio (INR) values on 2 or 3 consecutive
isits (4), and to have complete data for dose prediction by
ll dosing methods. Because of institutional review board
estrictions on access to individual, patient-level data for
linical and genetic variables for some of the patients in our
ohort, we could not determine the overall frequency of the
linical and genetic variables discussed in the following;
owever, these frequencies are summarized online for the
ubset of our patients who were part of the International
arfarin Pharmacogenetics Consortium cohort (n 
,025) (Online Table 1). Of note, predicted and actual
arfarin doses were available at the patient level for all
atients in our cohort.
ose prediction methods. EMPIRIC DOSE. Patients were
ssigned the population average dose of 35 mg/week.
LINICAL ALGORITHM. Patients were assigned a dose on
he basis of a formal regression equation (3). The factors
ncluded in this validated algorithm are age, body surface
rea (BSA), African American race, amiodarone usage,
arget INR, smoking status, and warfarin indication.
ARFARIN LABEL. Patients were assigned a dose equal to the
idpoint of the daily dose range provided in the table in the
ewly revised warfarin label (Table 1) (2). The exact methods
DA Label: Range of Expected Therapeutic Warfarin Doses (mg/daTable 1 FDA Label: Range of Expected Therapeutic Warfarin D
VKORC1-1639 CYP2C9 *1*1 CYP2C9 *1*2 CYP2
GG 5–7 5–7
GA 5–7 3–4
AA 3–4 3–4eproduced from updated warfarin (Coumadin, Bristol-Myers Squibb, Princeton, New Jersey) product labe
CYP2C9  cytochrome P450 2C9; FDA  U.S. Food and Drug Administration; VKORC1  vitamin K epsed by the Food and Drug Ad-
inistration to derive this table are
ot publicly available. Doses were
ultiplied by 7 to provide consis-
ent units of milligrams per week.
ENOTYPE MEAN TABLE. Pa-
ients were assigned the mean
ose in those with the same ge-
otype, on the basis of the
YP2C9 *2, CYP2C9 *3, and
KORC1 (1639 GA) genetic
ariants. Mean dose was deter-
ined in a separate population,
onsisting of the International Warfarin Pharmacogenetics
onsortium cohort minus those patients used in the analysis
ohort described previously (final n  2,858) (Table 2).
HARMACOGENETIC ALGORITHM. Patients were assigned
dose according to a previously validated formal regression
quation (3). This is similar to the algorithm available at
ww.warfarindosing.org; however, the online version has
een expanded since the original validation studies to also
ccommodate newer single-nucleotide polymorphisms that
ave minor effects on dose. Factors included in this algo-
ithm are CYP2C9 and VKORC1 genotype, age, BSA,
frican American race, amiodarone use, target INR, smok-
ng status, and warfarin indication.
ata analysis. The accuracy of each dosing method was
ased on whether the predicted dose fell within a clinically
eaningful range of within 20% of the stable therapeutic
ose, as used in other studies (4). Because this is a matched
ataset, the proportion of patients whose predicted doses
ell within this range was compared between each method
sing McNemar’s chi-square test. The resultant odds ratio
OR) in this test reflects the odds of patients’ being dosed
ithin range by one method versus the other. Comparisons
f all possible pairwise combinations of the 5 dosing
ethods were made, with no correction for multiple
omparisons.
Additionally, to quantify the extent to which each dosing
ethod was either overestimating or underestimating war-
arin dose, we examined the proportion of patients whose
redicted doses were above or below the stable therapeutic
ose by at least 20%. Finally, we examined the proportion of
atients predicted at therapeutic dose 20% on the basis of
hether the patient required a low (21 mg/week), inter-
Abbreviations
and Acronyms
BSA  body surface area
CI  confidence interval
CYP2C9  cytochrome
P450 2C9
INR  international
normalized ratio
OR  odds ratio
VKORC1  vitamin K
epoxide reductase complex
subunit 1
sed on CYP2C9 and VKORC1 Genotypes(mg/day) Based on CYP2C9 and VKORC1 Genotypes
*3 CYP2C9 *2*2 CYP2C9 *2*3 CYP2C9 *3*3
3–4 3–4 0.5–2
3–4 0.5–2 0.5–2
0.5–2 0.5–2 0.5–2l (2).
oxide reductase complex subunit 1.y) Baoses
C9 *1
3–4
3–4
0.5–2
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Genetic Warfarin Dosing: Tables Versus Algorithms February 1, 2011:612–8ediate (21 and 49 mg/week), or high (49 mg/week)
herapeutic dose of warfarin.
To explore how clinical judgment may affect the accuracy
f the warfarin label, we conducted a secondary analysis in
hich patients older than age 60 years (the cut point in the
arfarin label at which patients “appear to exhibit greater than
xpected [prothrombin time]/INR response to . . . warfarin”
2]) were assigned the lower estimate of the dose range,
nd patients age 60 years or younger were given the upper
stimate of the dose range. All principal analyses were
hen repeated. Additionally, we conducted a similar
econdary analysis incorporating more of the clinical
ariables used in the algorithms in the subset of patients
or which we had access to all of these variables at the
ndividual level. Patients were given the upper estimate of
he dose range in the warfarin label if they were age 60
ears, had BSAs 2.25 m2 (1 SD above the mean),
ere African American, or had target INRs 2.0 to 3.0.
atients were given the lower estimate of the dose range
n the warfarin label if they were age 60 years, had
SAs 1.75 m2, or used amiodarone. If patients had
WPC Cohort: Mean Therapeutic Warfarin Dose (mg/day) by CYP2CTable 2 IWPC Cohort: Mean Therapeutic Warfarin Dose (mg/d
VKORC1-1639 CYP2C9 *1*1 CYP2C9 *1*2 CYP2
GG 6 5
GA 5 4
AA 3 3
WPC  International Warfarin Pharmacogenetics Consortium; other abbreviations as in Table 1.
Figure 1 Dosing Method Accuracy
The proportion dosed within 20% of the stable therapeutic dose was calculated fo
of the therapeutic dose was considered a clinically meaningful degree of accuracyactors that both raised and lowered their predicted
arfarin doses, they were assigned the midpoint of the
ose range in the warfarin label.
To examine the effect of race on dosing method accuracy,
secondary analysis was conducted in which the cohort was
tratified by race and all principal analyses were repeated.
Analyses were performed using SPSS Statistics 17.0
SPSS, Inc., Chicago, Illinois) and SAS 9.1 (SAS Institute
nc., Cary, North Carolina).
esults
he percents of patients whose predicted doses were within
0% of their stable therapeutic doses for the empiric dose
37%), clinical algorithm (39%), warfarin label (43%), ge-
otype mean table (44%), and pharmacogenetic algorithm
52%) dosing methods are shown in Figure 1. The observed
ean therapeutic doses by genotype compared with the
oses predicted by the warfarin label and genotype mean
able are shown in Online Tables 2 and 3, respectively.
d VKORC1 Genotype in 2,858 Patientsy CYP2C9 and VKORC1 Genotype in 2,858 Patients
*3 CYP2C9 *2*2 CYP2C9 *2*3 CYP2C9 *3*3
4 4 3
3 2 1
2 1 2
dosing method. Having a predicted dose within 20%
bars indicate  1 SE.9 anay) b
C9 *1
4
3
2r each
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February 1, 2011:612–8 Genetic Warfarin Dosing: Tables Versus AlgorithmsAs shown in Figure 2, the pharmacogenetic algorithm
as significantly more accurate compared with each of the
ther dosing methods: empiric dose (OR: 2.18; 95% confi-
ence interval [CI]: 1.82 to 2.61), clinical algorithm (OR:
.17; 95% CI: 1.79 to 2.64), warfarin label (OR: 1.79; 95%
I: 1.48 to 2.17), and genotype mean table (OR: 1.85; 95%
I: 1.50 to 2.29). The 2 genetic tables were more accurate
han either the empiric dose or clinical algorithm. The
ifference between the warfarin label and genotype mean
ables was not statistically significant.
The extent of overestimation and underestimation of
arfarin dose by each dosing method is shown in Figure 3,
nd both were lowest with the pharmacogenetic algorithm.
dditionally, all methods performed best in patients requir-
ng intermediate warfarin doses. The pharmacogenetic al-
orithm performed better than all other methods in pre-
icting dose in those requiring higher (49 mg/week) and
ower (21 mg/week) doses (Online Fig. 1).
The age-adjusted warfarin label was minimally better
han the warfarin label based on the table midpoint (OR:
.16; 95% CI: 0.95 to 1.42), but the pharmacogenetic
lgorithm was still significantly better than the former
ethod (OR: 1.59; 95% CI: 1.31 to 1.93). The warfarin
abel adjusted for several clinical factors was minimally
etter than the warfarin label based on the table midpoint
OR: 1.12; 95% CI: 0.86 to 1.47) as well as the age-adjusted
arfarin label (OR: 1.21; 95% CI: 0.75 to 1.96), but it was
ignificantly worse than the pharmacogenetic algorithm
OR: 1.62; 95% CI: 1.29 to 2.05).
Figure 2 Two-Way Comparisons of Dosing Methods
The proportion dosed within 20% of stable therapeutic dose was compared using
the odds of a patient’s being properly dosed by the first method versus the seconThe percents of patients predicted at therapeutic dose 20%
or the empiric dose, clinical algorithm, warfarin label,
enotype mean table, and pharmacogenetic algorithm dos-
ng methods were 36%, 42%, 41%, 38%, and 42%, respec-
ively, in African Americans and 37%, 38%, 43%, 45%, and
4% in non–African Americans.
iscussion
ecent research on warfarin dose prediction has focused on
he use of formal pharmacogenetic algorithms based on
omplex regression equations. However, in January 2010,
he Food and Drug Administration updated the warfarin
abel to include pharmacogenetic dosing information in the
orm of a more straightforward table of estimated warfarin
ose, stratified by genotype. This change may potentially
ncrease the use of pharmacogenetic dose prediction by
linicians prescribing warfarin; thus, it is critical to deter-
ine the accuracy of this method. In this analysis, we
ompared the accuracy of these various dosing methods on
he basis of whether the predicted dose fell within a
linically meaningful range of within 20% of the stable
herapeutic dose, as done previously (4).
In our study, dosing based on genetic tables was some-
hat more accurate than that based on nongenetic methods.
sing the warfarin label or the genotype mean tables,
ccurate dosing could be predicted 43% or 44% of the time,
espectively, compared with 39% using a clinical algorithm
nd 37% using an empiric 5 mg/day dose. However, the
harmacogenetic algorithm was superior to all other meth-
ar’s chi-square test. The resultant odds ratio reflects
r bars represent exact 95% confidence intervals.McNem
d. Erro
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Genetic Warfarin Dosing: Tables Versus Algorithms February 1, 2011:612–8ds, including these tables. Using a pharmacogenetic algo-
ithm, accurate dose prediction was achieved 52% of the
ime. Furthermore, the pharmacogenetic algorithm had
ower rates of both dose overestimation and underestima-
ion than all other dosing methods (Fig. 3) as well as better
osing prediction in those requiring high and low warfarin
oses (Online Fig. 1).
Both genetic tables were found to be an improvement
ver empiric dosing and a clinical algorithm, affirming the
mportance of genetics in determining warfarin dose. Be-
ause both genetic tables performed similarly, it seems likely
hat their suboptimal performance relative to the pharma-
ogenetic algorithm is based on inherent limitations of
sing tables, rather than the result of inaccurate estimates.
ormal algorithms would be expected to more precisely
uantify the effects of multiple genetic factors on dose,
ompared with the average effects that are used in dosing
ables. Moreover, age, BSA, target INR, drug interactions,
nd other clinical factors have all previously been shown to
ffect warfarin dose (11). Thus, it is unsurprising that the
ombination of clinical factors with genotype in the context
f a formal pharmacogenetic algorithm seemed to be the most
eneficial for improving the accuracy of dose prediction.
The warfarin label does in fact state that clinical factors
hould be accounted for; however, it does not give guide-
ines on how both clinical and genetic factors should be
Figure 3 Dosing Method Accuracy
The proportions dosed below 80%, within 20%, and above 120% of the stable theombined to determine an appropriate dose. As a result, there was no way to formally test the impact of clinical
actors on the use of the genetic table in the warfarin label.
nalyses that approximated how clinicians may account for
linical factors led to minimal improvement in the accuracy
f the warfarin label; however, the formal pharmacogenetic
lgorithm remained superior.
One possible reason that adjusting for clinical factors did
ot result in more improvement in dosing accuracy is that
he magnitude of the effect on warfarin dose varies from
actor to factor and that level of complexity is difficult to
ccount for in a simple table. Additionally, another limita-
ion of the warfarin label is that it gives a wide relative
osing range for those most sensitive to the drug. Thus, any
implified table most likely will not be able to capture the
ull complexity of personalized warfarin dosing, because it
ill not be able to easily and accurately quantify the effects
f both genetic and clinical factors.
Nonetheless, even with the pharmacogenetic algorithm,
8% of patients were ultimately not dosed accurately. There
re several reasons why such a substantial proportion of
atients may not be dosed correctly. First, clinical factors
ther than those included in our study (and, to our knowl-
dge, not included in well-validated dosing algorithms) can
ffect warfarin dose (16–22). Second, genes other than
YP2C9 and VKORC1 may affect warfarin dose, such as
YP4F2, GGCX, EPHX1, and ApoE (14,23–25), although
ic dose were calculated for each dosing method.rapeutheir effects on warfarin dose require confirmation (26–28).
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February 1, 2011:612–8 Genetic Warfarin Dosing: Tables Versus Algorithmshese and other genes could be incorporated into future
harmacogenetic algorithms or tables to improve their accu-
acy; however, studies are needed to assess their clinical utility.
Finally, as expected on the basis of previous results
9,29,30), both the pharmacogenetic algorithm and the
enetic tables were less accurate in African Americans. In
act, the clinical algorithm seemed to perform just as well as
hese methods in African Americans, although our analysis
ohort did not have sufficient power to formally compare
osing methods within this group. To show their greatest
enefit, pharmacogenetic algorithms will likely have to
ncorporate genetic information from studies done in Afri-
an Americans. In short, it is clear that despite the extensive
mount of research that has been done on warfarin dosing
ariability, a substantial percent of that variability remains to
e explained (9,29–34).
Perhaps most important, although we know that phar-
acogenetic algorithms lead to more accurate warfarin dose
rediction, it remains unknown whether using a formal
harmacogenetic algorithm will actually improve laboratory
r clinical outcomes. Although some observational research
uggests that this may be the case (35), the answer to these
uestions awaits the results of large randomized clinical
rials that are currently under way (36–38).
The average cost of warfarin-related genetic testing is
urrently almost $400 per patient (39). This cost could fall
n the near future, making genotyping more feasible for routine
linical practice. However, given the substantial number of
atients started on warfarin each year, the added cost of
enotyping over the current standard of care will still be
ignificant. Thus, it is critical to use the information gained
rom genetic testing in the most effective way possible.
Our results suggest that the genetic table provided in the
pdated warfarin label is an improvement over empiric
osing and thus may be appropriate under certain circum-
tances. However, tables are less accurate than a formal
harmacogenetic algorithm for warfarin dose prediction. As
result, it seems advisable for clinicians to use a formal
harmacogenetic algorithm instead of a genetic dosing table
hen feasible. Should dosing algorithms prove effective at
mproving clinical outcomes in ongoing randomized trials,
ethods to improve access to these algorithms could include
ublication in the warfarin label, web-based access, and
ncorporation into handheld devices.
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niversity of Pennsylvania School of Medicine, Center for Clinical
pidemiology and Biostatistics, 717 Blockley Hall, 423 Guardian
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